Develops tumor-targeting peptide-drug conjugates for precise, antigen-independent delivery of potent anti-cancer therapies.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Cybrexa Therapeutics is a clinical-stage biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics that enable targeted intracellular delivery of highly potent anti-cancer agents. Its proprietary alphalex™ technology platform allows for antigen-independent targeting of tumors, aiming to revolutionize the standard of care in oncology by improving the precision and efficacy of cancer treatments.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Cybrexa Therapeutics Management Team
Investors
Elm Street Ventures
HighCape Partners
Cybrexa Therapeutics Valuations & Financials
View real-time NPM data on Cybrexa Therapeutics stock including daily Cybrexa Therapeutics stock price estimates, valuation history, and historical share price information. Access Cybrexa Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Cybrexa Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on Cybrexa Therapeutics? Get in touch to learn more.
Similar Companies
like Cybrexa Therapeutics
Podium
Enterprise Software
Customer messaging platform enabling companies to connect at critical touch points.
LayerZero Labs
Web3 & Digital Assets
Enables secure and seamless data and asset transfers between multiple blockchains, reducing transaction failures.
HuLoop
AI & Machine Learning
AI-powered automation platform that eliminates repetitive tasks through no-code solutions, enabling businesses to boost productivity and efficiency.
Colorescience
Consumer
Develops innovative mineral-based skincare and sun protection products that shield skin from environmental damage and harmful UV rays.
Poseidon Aerospace
Industrials
Transforms air logistics with autonomous cargo aircraft that lower cost per ton‑mile and reach areas beyond standard infrastructure.
Misfits Market
Consumer
Direct-to-consumer online grocer that reduces food waste and makes shopping for sustainable.
Panorays
Cybersecurity
Automated platform that assesses, monitors and manages third-party cybersecurity risks for businesses through comprehensive evaluations.
Hive AI
AI & Machine Learning
A software program company focusing on visual intelligence problems for producing unstructured visual data.
miRecule
Healthcare & Life Sciences
Innovates RNA treatments that target genetic causes to improve outcomes for hard‑to‑treat diseases.
FAQ
We have answers
Cybrexa Therapeutics stock does not trade on public stock exchanges. Cybrexa Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Cybrexa Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Cybrexa Therapeutics Stock does not trade on public stock exchanges. In order to sell Cybrexa Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Cybrexa Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Cybrexa Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Cybrexa Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Cybrexa Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Cybrexa Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Cybrexa Therapeutics is a private company and has not had an IPO. There is currently no Cybrexa Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Cybrexa Therapeutics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
